Patents by Inventor Bharat Kalidas Trivedi
Bharat Kalidas Trivedi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9206214Abstract: The inventions discloses a process for preparation of compounds of Formula (IX), Wherein, R is C1-C6 alkyl, R1 is hydrogen or a hydroxyl protecting group, and R2 is hydrogen or fluorine.Type: GrantFiled: February 29, 2012Date of Patent: December 8, 2015Assignee: Wockhardt Ltd.Inventors: Vijaykumar Jagdishwar Patil, Satish Birajdar, Bharat Dond, Bharat Kalidas Trivedi
-
Publication number: 20130296569Abstract: The invention relates to a process to prepare pharmacologically active phosphoric acid mono-(1-{4-[(S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,6-difluoro phenyl}-4-methoxy methyl-piperidin-4-yl)ester.Type: ApplicationFiled: February 3, 2011Publication date: November 7, 2013Inventors: Vijaykumar Jagdishwar Patil, Rajkumar Vishwanath Hangarge, Burhanuddin Munshi Zaki Ahmed, Loganathan Velupillai, Bharat Kalidas Trivedi
-
Patent number: 8541420Abstract: The invention relates to ketolide compound of Formula-I and the pharmaceutically acceptable salts thereof having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compound of invention.Type: GrantFiled: May 26, 2010Date of Patent: September 24, 2013Assignee: Wockhardt Ltd.Inventors: Bharat Kalidas Trivedi, Mahesh Vithalbhai Patel
-
Patent number: 8288416Abstract: The present invention relates to oxazolidinones of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof. The invention also relates to processes for the preparation of the compound of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof, and to pharmaceutical compositions containing the compounds of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof and to methods for treating or preventing microbial infections using the compounds of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof.Type: GrantFiled: September 22, 2007Date of Patent: October 16, 2012Assignee: Wockhardt Ltd.Inventors: Vijaykumar Jadgishwar Patil, Mahesh Vithalbhai Patel, Bharat Kalidas Trivedi, Deepak Vijaykumar Dekhane, Mohammad Usman Shaikh, Yati Chugh, Rajesh Prabhakar Chavan, Mohammad Alam Jafri
-
Publication number: 20120142710Abstract: The invention relates to ketolide compound of Formula-I and the pharmaceutically acceptable salts thereof having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compound of invention.Type: ApplicationFiled: May 26, 2010Publication date: June 7, 2012Inventors: Bharat Kalidas Trivedi, Mahesh Vithalbhai Patel
-
Patent number: 8097594Abstract: The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention relates to novel semi-synthetic 11,12-? lactone macrolides and ketolides having antimicrobial activity, processes for making compounds as well as pharmaceutical compositions containing said compounds as active ingredients and methods of treating microbial infections with the compounds.Type: GrantFiled: February 24, 2009Date of Patent: January 17, 2012Assignee: Wockhardt Ltd.Inventors: Milind Dattatraya Sindkhedkar, Vijaya Narayan Desai, Rajesh Maganlal Loriya, Mahesh Vithalbhai Patel, Bharat Kalidas Trivedi, Rajesh Onkardas Bora, Santosh Devidas Diwakar, Ganesh Rajaram Jadhav, Shivaji Sampatrao Pawar
-
Publication number: 20100120721Abstract: The present invention relates to oxazolidinones of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof. The invention also relates to processes for the preparation of the compound of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof, and to pharmaceutical compositions containing the compounds of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof and to methods for treating or preventing microbial infections using the compounds of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof.Type: ApplicationFiled: September 22, 2007Publication date: May 13, 2010Applicant: WOCKHARDT RESEARCH CENTREInventors: Vijaykumar Jadgishwar Patil, Mahesh Vithalbhai Patel, Bharat Kalidas Trivedi, Deepak Vijaykumar Dekhane, Mohammad Usman Shaikh, Yati Chugh, Rajesh Prabhakar Chavan, Mohammad Alam Jafri
-
Publication number: 20090247478Abstract: The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention relates to novel semi-synthetic 11,12-? lactone macrolides and ketolides having antimicrobial activity, processes for making compounds as well as pharmaceutical compositions containing said compounds as active ingredients and methods of treating microbial infections with the compounds.Type: ApplicationFiled: February 24, 2009Publication date: October 1, 2009Inventors: Milind Dattatraya Sindkhedkar, Vijaya Narayan Desai, Rajesh Maganlal Loriya, Mahesh Vithalbhai Patel, Bharat Kalidas Trivedi, Rajesh Onkardas Bora, Santosh Devidas Diwakar, Ganesh Rajaram Jadhav, Shivaji Sampatrao Pawar
-
Patent number: 6833380Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.Type: GrantFiled: December 19, 2002Date of Patent: December 21, 2004Assignee: Warner-Lambert Company, LLCInventors: Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
-
Publication number: 20030207916Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.Type: ApplicationFiled: December 19, 2002Publication date: November 6, 2003Inventors: Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
-
Publication number: 20030207924Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: ApplicationFiled: December 20, 2002Publication date: November 6, 2003Inventors: Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
-
Patent number: 6548499Abstract: Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.Type: GrantFiled: October 20, 2000Date of Patent: April 15, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Kenneth G. Carson, David Thomas Connor, Jie Jack Li, Joseph Edwin Low, Jay R. Luly, Steven Robert Miller, Bruce David Roth, Bharat Kalidas Trivedi
-
Patent number: 6534521Abstract: The present invention relates to novel compounds and medical methods of treatment of inflammation, atherosclerosis, restenosis, and immune disorders especially those associated with lymphocyte or monocyte accumulation such as arthritis and transplant rejection. More particularly, the present invention concerns the use of 2-phenyl benzimidazole derivatives.Type: GrantFiled: October 25, 2001Date of Patent: March 18, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: David Thomas Connor, Shelly Ann Glase, Terri Stoeber Purchase, Bruce David Roth, Bharat Kalidas Trivedi
-
Patent number: 6458806Abstract: Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection where V═O,S, NH or a bond; Ar can be unsubstituted or substituted benzimidazole, phenyl, biphenyl, pyridyl, naphthyl, quinoline or isoquinoline. The other meanings for the terms are recited in the specification below.Type: GrantFiled: August 12, 1997Date of Patent: October 1, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Richard John Booth, Kenneth Gordon Carson, David Thomas Connor, Roberta Ellen Glynn, Bruce David Roth, Charles F. Schwender, Bharat Kalidas Trivedi, Paul Charles Unangst
-
Publication number: 20020099054Abstract: Benzimidazole derivatives of Formula I or a pharmaceutically acceptable salt thereof are MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1Type: ApplicationFiled: October 25, 2001Publication date: July 25, 2002Applicant: Warner-Lambert CompanyInventors: David Thomas Connor, Shelly Ann Glase, Terri Stoeber Purchase, Bruce David Roth, Bharat Kalidas Trivedi
-
Publication number: 20020072606Abstract: The instant invention is a series of compounds which are MCP-1 receptor antagonists of Formula I 1Type: ApplicationFiled: July 5, 2001Publication date: June 13, 2002Applicant: Warner-Lambert CompanyInventors: Larry Don Bratton, Steven Robert Miller, Bruce David Roth, Bharat Kalidas Trivedi, Paul Charles Unangst
-
Publication number: 20020028833Abstract: Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1Type: ApplicationFiled: August 12, 1997Publication date: March 7, 2002Inventors: RICHARD JOHN BOOTH, KENNETH GORDON CARSON, DAVID THOMAS CONNOR, ROBERTA ELLEN GLYNN, BRUCE DAVID ROTH, CHARLES F. SCHWENDER, BHARAT KALIDAS TRIVEDI, PAUL CHARLES UNANGST
-
Patent number: 6348487Abstract: Benzimidazole derivatives of Formula I or a pharmaceutically acceptable salt thereof are MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders wherein A is N or CH; where W, X, Y, and Z can be independently C—R2, C—R3, C—R4, C—R5, or N; no more than two of W, X, Y, and Z can be N in any one structure, R2, R3, R4, and R5 are as define in the specification.Type: GrantFiled: October 27, 2000Date of Patent: February 19, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: David Thomas Connor, Shelly Ann Glase, Terri Stoeber Purchase, Bruce David Roth, Bharat Kalidas Trivedi
-
Patent number: 6316449Abstract: The instant invention is a series of compounds which are MCP-1 receptor antagonists of Formula I Also included in the invention are intermediates and processes for the preparation of the compounds as well as methods of using the compounds as agents for the treatment of atherosclerosis, chronic and acute inflammatory disease, chronic and acute immune disorders and transplant rejection as well as for preventing infection by HIV, treating infection by HIV, delaying the onset of AIDS, or treating AIDS.Type: GrantFiled: April 25, 2000Date of Patent: November 13, 2001Assignee: Millennium Pharmaceuticals, Inc.Inventors: Larry Don Bratton, Steven Robert Miller, Bruce David Roth, Bharat Kalidas Trivedi, Paul Charles Unangst
-
Patent number: 6184235Abstract: The present invention relates to novel compounds and medical methods of treatment of inflammation, atherosclerosis, restenosis, and immune disorders especially those associated with lymphocyte or monocyte accumulation such as arthritis and transplant rejection. More particularly, the present invention concerns the use of 2-phenyl benzimidazole derivatives.Type: GrantFiled: January 19, 1999Date of Patent: February 6, 2001Assignee: Warner-Lambert CompanyInventors: David Thomas Connor, Shelly Ann Glase, Terri Stoeber Purchase, Bruce David Roth, Bharat Kalidas Trivedi